Search results
Results from the WOW.Com Content Network
DOTA-TATE can be reacted with the radionuclides gallium-68 (T 1/2 = 68 min), lutetium-177 (T 1/2 = 6.65 d) and copper-64 (T 1/2 = 12.7 h) to form radiopharmaceuticals for positron emission tomography (PET) imaging or radionuclide therapy. 177 Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets ...
As well as diagnosis and staging of NETs, 68 Ga DOTA conjugated peptide imaging may be used for planning and dosimetry in preparation for lutetium-177 or yttrium-90 DOTA therapy. [35] [36] In June 2016, Netspot (kit for the preparation of gallium Ga-68 dotatate injection) was approved for medical use in the United States. [37] [38]
Gallium (68 Ga) gozetotide or Gallium (68 Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68 Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). [11]
[68 Ga] DOTA-pseudopeptides [68 Ga] DOTA-TATE [68 Ga] PSMA [68 Ga] CXCR4; solid and hematologic cancers; Infectious diseases. 18 F] Fluorodeoxysorbitol (FDS) Further ...
The shorter-lived gallium-68 (half-life 68 minutes) is a positron-emitting isotope generated in very small quantities from germanium-68 in gallium-68 generators or in much greater quantities by proton bombardment of 68 Zn in low-energy medical cyclotrons, [4] [5] for use in a small minority of diagnostic PET scans.
The parent isotope germanium-68 is the longest-lived (271 days) of the radioisotopes of germanium. It has been produced by several methods. [1] In the U.S., it is primarily produced in proton accelerators: At Los Alamos National Laboratory, it may be separated out as a product of proton capture, after proton irradiation of Nb-encapsulated gallium metal. [2]
A gastric emptying study is a nuclear medicine study which provides an assessment of the stomach's ability to empty.It may be used if there are complications after gastric surgery, for gastric reflux, or suspected gastroparesis amongst other indications. [1]
A phase I clinical trial of yttrium-90 labelled edotreotide concluded in 2011, [4] aiming to investigated effects in young cancer patients (up to 25 years of age). Specific cancers being included in the trial include neuroblastoma, childhood brain tumours and gastrointestinal cancer.